Metabolic Syndrome Raises Mortality Risk in Breast Cancer Survivors

Key Takeaways

• Among women with prior breast cancer in the UK Biobank, metabolic syndrome was present in 33.1% of survivors at baseline.
• Baseline MetS was associated with significantly higher long-term all-cause mortality, and mortality risk increased as MetS component burden increased.
• MetS was associated with incident MI, AF, and CKD, while stroke, HF, COPD, and depression were not statistically significant.

Long-term breast cancer survivorship increasingly includes cardiometabolic burden alongside cancer-related concerns. In this United Kingdom survivor population, metabolic syndrome (MetS) is common enough to make its long-range consequences clinically relevant.

Using the Frontiers in Endocrinology prospective UK Biobank study of metabolic syndrome in breast cancer survivors, investigators analyzed a population-based prospective cohort of women diagnosed with breast cancer more than 1 year before recruitment, excluding men and those without complete MetS assessment. The analysis included 1,997 of 6,027 survivors (33.1%) with MetS at baseline, defined as meeting at least 3 of 5 criteria: central obesity, elevated triglycerides or lipid-lowering treatment, elevated blood pressure or antihypertensive treatment, elevated fasting glucose or glucose-lowering treatment, and low high-density lipoprotein (HDL) cholesterol. All-cause mortality was the primary outcome, secondary outcomes included stroke, myocardial infarction (MI), atrial fibrillation (AF), heart failure, chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), and depression, and metabolomic analyses assessed 249 nuclear magnetic resonance (NMR) biomarkers. Follow-up was long enough to capture later mortality and noncancer comorbidity.

Over a median 15.7 years of follow-up (IQR 15.1 to 16.4), 1,251 deaths occurred. Baseline MetS was associated with higher all-cause mortality after multivariable adjustment (HR 1.23; 95% CI 1.08 to 1.41; p=0.002), and mortality risk rose as the number of MetS components increased. The excess signal was more apparent for non-cancer-specific death (HR 1.45; 95% CI 1.13 to 1.86), while cancer-specific and cardiovascular-specific mortality were not statistically significant.

In the study’s main results, MetS was associated with higher incident myocardial infarction (HR 1.56; 95% CI 1.02 to 2.40), atrial fibrillation (HR 1.61; 95% CI 1.04 to 2.49), and chronic kidney disease (HR 1.98; 95% CI 1.56 to 2.51), while stroke and heart failure were not significant overall; chronic obstructive pulmonary disease and depression were also not significantly associated overall, and chronic kidney disease risk increased further with greater MetS burden. Mediation analyses implicated fatty acid composition and inflammation-related measures, including polyunsaturated fatty acid (PUFA)-related ratios and glycoprotein acetyls (GlycA), as potential mediators.

Because the study was observational, the mortality and mediation associations should not be interpreted as causal effects. The authors noted that the cohort was predominantly White and relatively socially advantaged, residual confounding may persist despite adjustment, treatment-phase and molecular subtype data were incomplete, physical activity had substantial missingness, and MetS was assessed only at baseline rather than over time.

The researchers concluded that baseline MetS in this cohort tracked with higher long-term all-cause mortality and higher incidence of selected cardiometabolic comorbidities. They also reported that the excess mortality signal appeared more evident for non-cancer causes than for cancer-specific or cardiovascular-specific death. The metabolomic findings pointed to fatty acid composition and inflammation as possible pathways rather than proving causation.

Clinician Questions

How was metabolic syndrome defined in breast cancer survivors in the UK Biobank cohort?

Metabolic syndrome was defined at study entry as meeting at least 3 of 5 criteria: central obesity, elevated triglycerides or lipid-lowering treatment, elevated blood pressure or antihypertensive treatment, elevated fasting glucose or glucose-lowering treatment, and low HDL cholesterol.

Which deaths appeared to drive the mortality association between metabolic syndrome and breast cancer survivorship?

The excess signal was more apparent for non-cancer-specific death in the competing-risk analysis, while cancer-specific and cardiovascular-specific mortality were not statistically significant.

Did the association between metabolic syndrome and adverse outcomes vary by subgroup in breast cancer survivors?

Subgroup analyses suggested more pronounced mortality associations among survivors with overweight body mass index and among never-smokers, with additional signals for heart failure by body mass index and COPD by smoking status.

What metabolomic patterns were proposed as potential mediators of mortality risk in breast cancer survivors with metabolic syndrome?

Mediation analyses pointed to fatty acid composition and inflammation-related measures as potential mediators, including the PUFA-to-total fatty acids ratio, the PUFA-to-MUFA ratio, the triglycerides-to-total lipids ratio in small HDL, and GlycA, without establishing a causal pathway.